<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744287</url>
  </required_header>
  <id_info>
    <org_study_id>BP-012</org_study_id>
    <nct_id>NCT02744287</nct_id>
  </id_info>
  <brief_title>Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in&#xD;
      participants with previously treated advanced solid tumors (pancreatic and prostate)&#xD;
      expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are&#xD;
      modified to recognize and target the PSCA tumor marker on cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to characterize the feasibility, safety, and clinical activity of&#xD;
      PSCA-specific CAR-T cells, BPX-601, administered with rimiducid to subjects with previously&#xD;
      treated, PSCA-positive advanced solid tumors (pancreatic or prostate). BPX-601 CAR-T cells&#xD;
      are genetically engineered to express a chimeric antigen receptor (CAR) to target the PSCA&#xD;
      antigen and a rimiducid-inducible signaling domain which functions as a molecular &quot;go-switch&quot;&#xD;
      to enhance activation and proliferation.&#xD;
&#xD;
      Phase 1: Cell dose escalation to identify the maximum dose of BPX-601 administered with&#xD;
      single or repeat doses of rimiducid (fixed dose of 0.4 mg/kg per infusion).&#xD;
&#xD;
      Phase 2: Indication-specific dose expansion to assess the safety, pharmacodynamics (including&#xD;
      BPX-601 persistence), and clinical activity at the recommended dose identified in Phase 1 in&#xD;
      various PSCA-expressing solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>4 weeks after first rimiducid infusion (i.e., Day 35)</time_frame>
    <description>Incidence of dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent adverse events (AEs) and serious AEs (SAEs)</measure>
    <time_frame>180 days after BPX-601 treatment up to 15 years</time_frame>
    <description>Number of participants with adverse events (AEs) and serious AEs (SAEs) assessed for severity using NCI CTCAE v4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)</measure>
    <time_frame>through Phase 1 completion, up to 5 years</time_frame>
    <description>Identify the optimal dose of BPX-601 with rimiducid for Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of BPX-601</measure>
    <time_frame>up to 1 year after treatment</time_frame>
    <description>Change from baseline in pharmacodynamic blood biomarkers - markers of BPX-601 CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of BPX-601</measure>
    <time_frame>From the time of BPX-601 cell infusion until confirmed disease progression or death due to any cause, the start of new anticancer therapy, or withdrawal, whichever comes first, as assessed for up to 5 years after the last subject has been enrolled</time_frame>
    <description>Percentage of subjects with objective response determined by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the Prostate Cancer Working Group 3 (PCWG3) criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Phase 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced pancreatic or prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Phase 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced pancreatic or prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BPX-601</intervention_name>
    <description>Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain</description>
    <arm_group_label>Arm 1: Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Arm 2: Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimiducid</intervention_name>
    <description>Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence</description>
    <arm_group_label>Arm 1: Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Arm 2: Phase 2 Dose Expansion</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic pancreatic cancer with tumor progression within 6 months of the most recent&#xD;
             anti-cancer treatment and documented positive tumor expression of PSCA, and prior&#xD;
             treatment with first or second-line therapy; or,&#xD;
&#xD;
          -  Metastatic castration-resistant prostate cancer (mCRPC), with progressive disease per&#xD;
             PCWG3 criteria during or following the direct prior line of therapy.&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1 at baseline; subjects with mCRPC with bone only&#xD;
             metastases must have measurable PSA.&#xD;
&#xD;
          -  Age â‰¥18 years.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pancreatic cancer with islet cell neoplasms or symptomatic/untreated coagulopathy.&#xD;
&#xD;
          -  Prostate cancer with unstable bone lesions or symptomatic/untreated coagulopathy, or&#xD;
             history of &gt; Grade 2 hematuria within the previous 6 months.&#xD;
&#xD;
          -  Prior CAR T cell or other genetically-modified T cell therapy. Prior treatment with an&#xD;
             immune-based therapy for the treatment of prostate cancer, including cancer vaccine&#xD;
             therapies are allowable.&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing central nervous system metastases.&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Participant requires chronic, systemic steroid therapy.&#xD;
&#xD;
          -  Severe intercurrent infection.&#xD;
&#xD;
          -  Known HIV positivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BPX-601 Study Team</last_name>
    <phone>832-384-1100</phone>
    <email>012mail@bellicum.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Won Kim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Akce, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulam Manji, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gulam Manji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Becerra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ecaterina Dumbrava, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate stem cell antigen</keyword>
  <keyword>BPX-601</keyword>
  <keyword>AP1903</keyword>
  <keyword>CAR-T</keyword>
  <keyword>PSCA-CAR</keyword>
  <keyword>castration-resistant prostate cancer</keyword>
  <keyword>rimiducid</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>PSCA</keyword>
  <keyword>CRPC</keyword>
  <keyword>mCRPC</keyword>
  <keyword>PDAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

